Clinical Trial Update: A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection [Phase 3]

View source ↗

Summary

This Phase 3 study evaluating daclatasvir and sofosbuvir with ribavirin in patients with cirrhosis and genotype 3 hepatitis C has completed, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Cirrhosis

Drugs mentioned

• Copegus (ribavirin)
• Daklinza (Daclatasvir)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2018-03-29